FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic CancerThierry Conroy, Jean‐Baptiste Bachet, Pascal Hammel et al.|New England Journal of Medicine|2018Cited by 2.8k
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trialJordi Bruix, Josep M. Llovet, Jean‐Luc Raoul et al.|Journal of Hepatology|2012Cited by 821
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL StudyPhilip J. Johnson, Ann‐Lii Cheng, Éveline Boucher et al.|Journal of Clinical Oncology|2013Cited by 775
Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS StudyJosep M. Llovet, Joong‐Won Park, Thomas Decaens et al.|Journal of Clinical Oncology|2013Cited by 596
Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trialThierry Conroy, Antoine Adenis, Jean‐Luc Raoul et al.|The Lancet Oncology|2014Cited by 446